FDA Requests Removal of Suicidal Ideation Warning From Certain GLP-1 Labels

FDA says it is requesting that drug application holders remove information regarding suicidal ideation and behavior from the labeling of Saxenda, Wegovy, and Zepbound after a comprehensive review found no increased risk with GLP-1 receptor agonist use. FDA says its meta-analysis covered 91 placebo-controlled GLP-1 RA trials involving 107,910 patients.

This is an important pharmacovigilance story because it shows that evidence can move labeling in both directions. Sometimes safety review adds warnings; sometimes it narrows or removes them when the evidence does not support continued concern. That interpretation follows from FDA’s announced request to remove existing warning language.